Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems

By Oktay Tacar, P. Sriamornsak, C. Dass. The Journal of pharmacy and pharmacology, 2013

2,347 citations recorded by the source corpus.

Subfields: Biomaterials, Cardiology and Cardiovascular Medicine, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/06199e1e2dd0d9d4ded310c29a774fe329aaddd3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Anastasia Baryshnikova

Citations in the corpus

• Systematic Functional Annotation and Visualization of Biological Networks (2016, background): “…doxorubicin, a DNA intercalator that prevents DNA replication by blocking the progression of topoisomerase II (Momparler et al., 1976; Fornari et al., 1994; Tacar et al., 2013), were specifically enriched within the network region associated with DNA replication and repair GO terms ( Figure 4A ).”
• Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity (2023, background): “Moreover, damage to other organs [11–13], including the brain [12,14,15], liver [16], and kidneys [17–19], can also occur.”
• Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. (2016, neutral): “typhlitis (Tacar et al., 2013)”